RU2015114990A - Способы, композиции и приборы для облегчения регенерации - Google Patents

Способы, композиции и приборы для облегчения регенерации Download PDF

Info

Publication number
RU2015114990A
RU2015114990A RU2015114990/10A RU2015114990A RU2015114990A RU 2015114990 A RU2015114990 A RU 2015114990A RU 2015114990/10 A RU2015114990/10 A RU 2015114990/10A RU 2015114990 A RU2015114990 A RU 2015114990A RU 2015114990 A RU2015114990 A RU 2015114990A
Authority
RU
Russia
Prior art keywords
antibody
conjugated
toxin
humanized
cell
Prior art date
Application number
RU2015114990/10A
Other languages
English (en)
Other versions
RU2640249C2 (ru
Inventor
Льюис С. ГРУБЕР
Original Assignee
Сива Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сива Корпорейшн filed Critical Сива Корпорейшн
Publication of RU2015114990A publication Critical patent/RU2015114990A/ru
Application granted granted Critical
Publication of RU2640249C2 publication Critical patent/RU2640249C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452—Skin
    • A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N7/02—Localised ultrasound hyperthermia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Electromagnetism (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)

Abstract

1. Гуманизированное антитело, которое связывается с конечным продуктом гликирования клетки.2. Гуманизированное антитело по п. 1, где антитело является моноклональным антителом.3. Гуманизированное антитело по п. 1, где антитело конъюгировано с токсином.4. Гуманизированное антитело по п. 2, где антитело конъюгировано с токсином.5. Применение антитела, которое связывается с конечным продуктом гликирования клетки, для промотирования регенерации ткани или органа у пациента путем уничтожения частично функциональных или не функциональных клеток, которые содержат указанный конечный продукт гликирования клетки.6. Применение по п. 5, где антитело является гуманизированным.7. Применение по п. 5, где антитело является моноклональным антителом.8. Применение по п. 5, где антитело конъюгировано с токсином.9. Применение по п. 6, где антитело является моноклональным антителом.10. Применение по п. 6, где антитело конъюгировано с токсином.11. Применение по п. 7, где антитело конъюгировано с токсином.12. Применение по п. 9, где антитело конъюгировано стоксином.13. Применение композиции для промотирования регенеративных процессов или для преодоления эффектов старения, где композиция селективно уничтожает стареющие клетки, при этом композиция содержит антитела, которые связываются с конечным продуктом гликирования клетки.14. Применение по п. 13, где антитело является гуманизированным.15. Применение по п. 13, где антитело является моноклональным антителом.16. Применение по п. 13, где антитело конъюгировано с токсином.17. Применение по п. 14, где антитело является моноклональным антителом.18. Применение по п. 14, где антитело конъюгировано с токсином.19. Приме�

Claims (20)

1. Гуманизированное антитело, которое связывается с конечным продуктом гликирования клетки.
2. Гуманизированное антитело по п. 1, где антитело является моноклональным антителом.
3. Гуманизированное антитело по п. 1, где антитело конъюгировано с токсином.
4. Гуманизированное антитело по п. 2, где антитело конъюгировано с токсином.
5. Применение антитела, которое связывается с конечным продуктом гликирования клетки, для промотирования регенерации ткани или органа у пациента путем уничтожения частично функциональных или не функциональных клеток, которые содержат указанный конечный продукт гликирования клетки.
6. Применение по п. 5, где антитело является гуманизированным.
7. Применение по п. 5, где антитело является моноклональным антителом.
8. Применение по п. 5, где антитело конъюгировано с токсином.
9. Применение по п. 6, где антитело является моноклональным антителом.
10. Применение по п. 6, где антитело конъюгировано с токсином.
11. Применение по п. 7, где антитело конъюгировано с токсином.
12. Применение по п. 9, где антитело конъюгировано с
токсином.
13. Применение композиции для промотирования регенеративных процессов или для преодоления эффектов старения, где композиция селективно уничтожает стареющие клетки, при этом композиция содержит антитела, которые связываются с конечным продуктом гликирования клетки.
14. Применение по п. 13, где антитело является гуманизированным.
15. Применение по п. 13, где антитело является моноклональным антителом.
16. Применение по п. 13, где антитело конъюгировано с токсином.
17. Применение по п. 14, где антитело является моноклональным антителом.
18. Применение по п. 14, где антитело конъюгировано с токсином.
19. Применение по п. 15, где антитело конъюгировано с токсином.
20. Применение по п. 17, где антитело конъюгировано с токсином.
RU2015114990A 2008-05-23 2009-05-22 Способы, композиции и приборы для облегчения регенерации RU2640249C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5584608P 2008-05-23 2008-05-23
US61/055,846 2008-05-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2010152693/10A Division RU2553225C2 (ru) 2008-05-23 2009-05-22 Способ облегчения регенерации

Publications (2)

Publication Number Publication Date
RU2015114990A true RU2015114990A (ru) 2015-11-27
RU2640249C2 RU2640249C2 (ru) 2017-12-27

Family

ID=41340916

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010152693/10A RU2553225C2 (ru) 2008-05-23 2009-05-22 Способ облегчения регенерации
RU2015114990A RU2640249C2 (ru) 2008-05-23 2009-05-22 Способы, композиции и приборы для облегчения регенерации

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2010152693/10A RU2553225C2 (ru) 2008-05-23 2009-05-22 Способ облегчения регенерации

Country Status (18)

Country Link
US (4) US20110105961A1 (ru)
EP (3) EP2294178B1 (ru)
JP (6) JP2011521009A (ru)
KR (4) KR20120127543A (ru)
CN (2) CN102037119B (ru)
AU (1) AU2009248945B2 (ru)
BR (1) BRPI0913047A2 (ru)
CA (1) CA2724886C (ru)
DK (1) DK2789684T3 (ru)
ES (2) ES2499395T3 (ru)
HU (1) HUE031902T2 (ru)
IL (3) IL209513A (ru)
MX (2) MX342994B (ru)
PL (1) PL2789684T3 (ru)
PT (1) PT2789684T (ru)
RU (2) RU2553225C2 (ru)
WO (1) WO2009143411A2 (ru)
ZA (1) ZA201008209B (ru)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10226531B2 (en) 2010-09-27 2019-03-12 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US10960234B2 (en) 2010-11-22 2021-03-30 Siwa Corporation Selective removal of cells having accumulated agents
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2499395T3 (es) 2008-05-23 2014-09-29 Siwa Corporation Procedimientos para facilitar la regeneración
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
CN104125836A (zh) 2011-12-13 2014-10-29 巴克老龄化研究所 改善医疗治疗的方法
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
WO2014089124A1 (en) 2012-12-03 2014-06-12 Cenexys, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
US20160051700A1 (en) 2013-03-24 2016-02-25 Oisin Biotechnologies Systems and methods for the targeted production of a therapeutic protein within a target cell
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
CN112274641A (zh) 2014-01-28 2021-01-29 巴克老龄化研究所 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
JP2018535953A (ja) 2015-10-13 2018-12-06 シワ コーポレーション 抗ａｇｅ抗体およびその使用方法
CA3021150C (en) 2016-02-19 2023-02-07 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
WO2017181116A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
WO2018129563A1 (en) 2017-01-09 2018-07-12 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
KR20200003067A (ko) 2017-05-04 2020-01-08 시와 코퍼레이션 진단용 최종 당화 산물 항체
EP3784252A4 (en) 2018-04-18 2022-03-16 Oisin Biotechnologies, Inc. FUSOGENIC LIPID DNANOPARTICLES AND METHODS FOR THEIR PRODUCTION AND USE IN TARGET CELL SPECIFIC MANUFACTURE OF A THERAPEUTIC PROTEIN AND TREATMENT OF A TARGET CELL RELATED DISEASE, CONDITION OR DISORDER
JP2021532114A (ja) * 2018-07-23 2021-11-25 シワ コーポレーション 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物
EP3840840A1 (en) 2018-08-23 2021-06-30 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
KR20210101481A (ko) * 2020-02-10 2021-08-19 한국과학기술연구원 초음파 출력부를 포함하는 노화세포 제거 장치
CA3177449A1 (en) 2020-05-01 2021-11-04 Lewis S. Gruber Methods of treating infections
WO2022093195A1 (en) 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
KR102650316B1 (ko) * 2021-06-18 2024-03-25 재단법인대구경북과학기술원 초음파 자극이 가능한 자성 패치 및 그 제작 방법
CA3229602A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
WO2024102157A1 (en) 2022-11-09 2024-05-16 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US5811075A (en) 1984-03-19 1998-09-22 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US4900747A (en) * 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
JP2644767B2 (ja) * 1986-09-12 1997-08-25 ザ ロックフェラー ユニバーシティ 後生的なグリコシル化最終産物を除去する為の方法及び薬剤
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) * 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4965288A (en) * 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040208826A1 (en) * 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
IN172208B (ru) * 1990-04-02 1993-05-01 Sint Sa
US20080063603A1 (en) * 1990-04-02 2008-03-13 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
JP3533217B2 (ja) 1991-12-20 2004-05-31 テクノメド メディカル システム 熱効果およびキャビテーション効果を有する超音波を出力する超音波治療装置
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
US5620479A (en) * 1992-11-13 1997-04-15 The Regents Of The University Of California Method and apparatus for thermal therapy of tumors
US5518720A (en) * 1992-12-30 1996-05-21 Exocell, Inc. Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
US6387373B1 (en) * 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
JPH09500102A (ja) * 1993-04-28 1997-01-07 ウォーセスター ファウンデーション フォー エクスペリメンタル バイオロジー 細胞指向性溶解孔形成剤
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
AU692237B2 (en) 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5744318A (en) * 1994-12-30 1998-04-28 Alteon Inc. Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples
IL116617A (en) * 1994-12-30 2001-09-13 Alteon Inc Monoclonal antibody 4g9, 2g6 or bh4, or an antigen binding fragment thereof reactive with in vivo produced advanced glycosylation endproducts
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
AU6907496A (en) 1995-08-25 1997-03-19 Case Western Reserve University Process for detecting pentosidine and for assessing the biological age of a biological sample
JP3579549B2 (ja) 1995-10-24 2004-10-20 株式会社トクヤマ 糖尿病または糖尿病合併症用マーカーとしての使用
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5664570A (en) 1996-02-20 1997-09-09 Svc Apparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body
US5908925A (en) * 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5984882A (en) * 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6245318B1 (en) * 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
AU8693598A (en) * 1997-08-08 1999-03-01 University Of Washington Isolation of a novel senescence-factor gene, p23
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6896659B2 (en) * 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
JP4016304B2 (ja) 1998-02-26 2007-12-05 日本油脂株式会社 モノクローナル抗体、ハイブリッド細胞、およびモノクローナル抗体の製造方法
JP2002517224A (ja) * 1998-06-09 2002-06-18 アルテオン インコーポレーテッド 生体サンプル内におけるグアニジノ基由来進行グリコシル化最終生成物に特異的なモノクローナル抗体
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
HK1041293B (en) * 1998-10-06 2008-01-25 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US6309355B1 (en) * 1998-12-22 2001-10-30 The Regents Of The University Of Michigan Method and assembly for performing ultrasound surgery using cavitation
PT1159003E (pt) 1999-03-02 2011-02-22 Centocor Inc Anti-tnf alfa na terapêutica da asma resistente a esteróides
US6067859A (en) * 1999-03-04 2000-05-30 The Board Of Regents, The University Of Texas System Optical stretcher
AU784045B2 (en) 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003507013A (ja) * 1999-08-13 2003-02-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果
EP1219639A4 (en) 1999-09-08 2009-03-25 Toray Industries CIPO - Patent
US6853864B2 (en) 2000-02-02 2005-02-08 Catholic University Of America, The Use of electromagnetic fields in cancer and other therapies
WO2001089584A2 (en) * 2000-05-23 2001-11-29 Amersham Health As Contrast agents
NO312338B1 (no) * 2000-08-25 2002-04-29 Gunnar Myhr Anordning for selektiv celle- eller virusödeleggelse hos en levende organisme
CN2445326Y (zh) * 2000-10-09 2001-08-29 刘永详 测定被糖化蛋白的免疫分析装置
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7481781B2 (en) * 2000-11-17 2009-01-27 Gendel Limited Ultrasound therapy
US6821274B2 (en) * 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
EP1362223B1 (en) 2001-01-03 2008-05-21 Ultrashape Inc. Non-invasive ultrasonic body contouring
US7347855B2 (en) 2001-10-29 2008-03-25 Ultrashape Ltd. Non-invasive ultrasonic body contouring
DE60202008T2 (de) * 2001-03-22 2005-12-01 Roche Diagnostics Gmbh Verfahren zum Auffinden von Reagenzien und Festphasenkomponenten in spezifischen Bindungsassays, frei von fortgeschrittenen Glykosylierungsendprodukten
US20040210042A1 (en) 2001-07-19 2004-10-21 Tsuchida Jun-Ichi Polypeptides relating to signal transfer of advanced glycation end product receptor
JP4012722B2 (ja) 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ATE547416T1 (de) * 2002-07-24 2012-03-15 Dermira Canada Inc Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
CA2495663A1 (en) 2002-08-16 2004-02-26 Wyeth Compositions and methods for treating rage-associated disorders
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2004079368A2 (en) * 2003-03-08 2004-09-16 Auvation Ltd Markers for colorectal cancer
US20060122543A1 (en) * 2003-07-31 2006-06-08 Woodwelding Ag Method for promoting tissue regeneration on wound surfaces as device and treatment instrument or implant for carrying out method
US7358226B2 (en) * 2003-08-27 2008-04-15 The Regents Of The University Of California Ultrasonic concentration of drug delivery capsules
EP2213310A1 (en) * 2004-01-20 2010-08-04 Sunnybrook and Women's College Health Sciences Centre High frequency ultrasound imaging using contrast agents
WO2005079463A2 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
WO2006012415A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
BRPI0514052A (pt) 2004-08-03 2008-05-27 Transtech Pharma Inc proteìnas de fusão rage e métodos de utilização
GB0422525D0 (en) 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2006094951A1 (en) * 2005-03-03 2006-09-14 Bracco Research Sa Medical imaging system based on a targeted contrast agent
JP2006249015A (ja) * 2005-03-11 2006-09-21 Mochida Pharmaceut Co Ltd 細胞老化抑制剤
WO2006109599A1 (ja) 2005-04-05 2006-10-19 Jms Co., Ltd. 3,4-DGEに由来するAGEsに特異的に反応する抗体
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20070059247A1 (en) * 2005-08-30 2007-03-15 Lindner Jonathan R Deposit contrast agents and related methods thereof
US20070065415A1 (en) * 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
US20070083120A1 (en) * 2005-09-22 2007-04-12 Cain Charles A Pulsed cavitational ultrasound therapy
US20070078290A1 (en) * 2005-09-30 2007-04-05 Esenaliev Rinat O Ultrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues
US7766833B2 (en) * 2005-11-23 2010-08-03 General Electric Company Ablation array having independently activated ablation elements
JP4779115B2 (ja) 2005-12-16 2011-09-28 国立大学法人東北大学 早期肺癌の術後予後検査方法
EP1988918A4 (en) * 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
PL2676967T3 (pl) 2006-02-28 2019-12-31 Biogen Ma Inc. Metody leczenia chorób zapalnych i autoimmunologicznych za pomocą natalizumabu
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
WO2008154638A2 (en) 2007-06-12 2008-12-18 Board Of Regents, The University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)
RU2513695C2 (ru) 2007-06-14 2014-04-20 Гэлэктика Фармасьютикалс, Инк. Слитые белки rage
JP2007277263A (ja) 2007-07-13 2007-10-25 Transgenic Inc カルボキシメチル化タンパク質に対する抗体
WO2009085216A2 (en) * 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
US7751057B2 (en) * 2008-01-18 2010-07-06 The Board Of Trustees Of The University Of Illinois Magnetomotive optical coherence tomography
DE102008009461A1 (de) 2008-02-15 2009-08-20 Beiersdorf Ag Verfahren zur Reduzierung der Zeichen der Hautalterung
CN102089430B (zh) * 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途
ES2499395T3 (es) 2008-05-23 2014-09-29 Siwa Corporation Procedimientos para facilitar la regeneración
JP5229473B2 (ja) * 2008-06-04 2013-07-03 財団法人ヒューマンサイエンス振興財団 超音波医療装置
US20110319499A1 (en) 2008-06-30 2011-12-29 The Johns Hopkins University Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease
WO2010095461A1 (ja) 2009-02-20 2010-08-26 国立大学法人東京大学 新規モノクローナル抗体、並びにその使用
US8343420B2 (en) * 2009-09-17 2013-01-01 Sanuwave, Inc. Methods and devices for cleaning and sterilization with shock waves
US20110070227A1 (en) 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
US20130058921A1 (en) 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
WO2011101039A1 (en) 2010-02-22 2011-08-25 Universite Pierre Et Marie Curie (Paris 6) Apparatus for the treatment of brain affections and method implementing thereof
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
WO2012047629A2 (en) 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012135616A1 (en) 2011-03-31 2012-10-04 Siwa Corporation Vaccination against advanced glycation end-products
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
KR102068724B1 (ko) 2011-07-10 2020-01-21 가이디드 테라피 시스템스, 엘.엘.씨. 에너지원으로 초음파를 이용한 피부 외양을 개선하는 시스템 및 방법
US8954155B2 (en) 2011-09-19 2015-02-10 Biotalk Technologies Inc Apparatus and method for rejuvenating skin
AU2012311428A1 (en) 2011-09-23 2014-04-24 Julius-Maximilians-Universitat Wurzburg Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
KR101939401B1 (ko) 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
EA031069B1 (ru) 2012-02-17 2018-11-30 Сиэтл Дженетикс, Инк. АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
US20130288980A1 (en) 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent and cancer cells for selective killing by interference with foxo4
US10379026B2 (en) 2012-08-29 2019-08-13 Inguran, Llc Cell processing using magnetic particles
KR101520336B1 (ko) 2012-11-30 2015-05-14 전남대학교산학협력단 패혈증 비브리오균의 편모 구성성분인 플라젤린과 병원체의 항원 단백을 융합시킨 재조합 단백을 포함하는 노화 예방, 개선 또는 치료용 조성물
EP2742935A1 (en) 2012-12-14 2014-06-18 Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH SERF2 for the treatment of atrophy and for increasing cell growth
WO2014136114A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
US20140257262A1 (en) 2013-03-11 2014-09-11 Alexandre Carpentier Interstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same
HRP20200553T1 (hr) 2013-03-12 2020-07-10 Molecular Templates, Inc. Citotoksični proteini koji sadrže vezne regije koje ciljaju na stanice i regije podjedinice a shiga toksina za selektivno ubijanje specifičnih tipova stanica
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
AU2015206515B2 (en) 2014-01-15 2019-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cartilage targeting agents and their use
US10099027B2 (en) 2014-01-24 2018-10-16 Cole Research & Design Oral suction device
CN112274641A (zh) 2014-01-28 2021-01-29 巴克老龄化研究所 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
DE102014107077B3 (de) 2014-05-20 2015-08-13 Ecs Engineered Control Systems Ag Schaltvorrichtung
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US20170240632A1 (en) 2014-10-16 2017-08-24 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
JP2018535953A (ja) 2015-10-13 2018-12-06 シワ コーポレーション 抗ａｇｅ抗体およびその使用方法
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
KR102503910B1 (ko) 2015-11-09 2023-02-27 삼성전자주식회사 기립 보조 방법 및 장치
CA3021150C (en) 2016-02-19 2023-02-07 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
US10981021B2 (en) 2016-03-11 2021-04-20 Carthera Method for transiently disrupting a region of the blood-brain barrier of a human
WO2017181116A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) * 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
KR20200003067A (ko) 2017-05-04 2020-01-08 시와 코퍼레이션 진단용 최종 당화 산물 항체
JP2021532114A (ja) 2018-07-23 2021-11-25 シワ コーポレーション 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物
EP3837359A4 (en) 2018-08-14 2022-05-11 Imel Biotherapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DISORDERS AND HETEROPLASMIA
EP3840840A1 (en) 2018-08-23 2021-06-30 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
CA3177449A1 (en) 2020-05-01 2021-11-04 Lewis S. Gruber Methods of treating infections
WO2021247397A2 (en) 2020-06-04 2021-12-09 Siwa Corporation Methods and compositions for enhancing the immune system

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226531B2 (en) 2010-09-27 2019-03-12 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US10960234B2 (en) 2010-11-22 2021-03-30 Siwa Corporation Selective removal of cells having accumulated agents
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US11873345B2 (en) 2014-12-18 2024-01-16 Siwa Corporation Product and method for treating sarcopenia
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Also Published As

Publication number Publication date
JP2015131846A (ja) 2015-07-23
EP2294178A2 (en) 2011-03-16
KR20120127543A (ko) 2012-11-21
US20160152697A1 (en) 2016-06-02
JP2020050666A (ja) 2020-04-02
IL209513A (en) 2015-08-31
CN102037119A (zh) 2011-04-27
US11261241B2 (en) 2022-03-01
HUE031902T2 (en) 2017-08-28
CN104987416A (zh) 2015-10-21
KR20130132658A (ko) 2013-12-04
CA2724886C (en) 2017-11-14
IL209513A0 (en) 2011-01-31
JP2016152815A (ja) 2016-08-25
EP2294178B1 (en) 2014-07-16
RU2640249C2 (ru) 2017-12-27
RU2553225C2 (ru) 2015-06-10
EP2789684B1 (en) 2016-12-21
CN102037119B (zh) 2015-06-24
BRPI0913047A2 (pt) 2013-03-05
ES2499395T3 (es) 2014-09-29
US9161810B2 (en) 2015-10-20
HK1150628A1 (en) 2012-01-06
AU2009248945A1 (en) 2009-11-26
WO2009143411A3 (en) 2010-01-14
US20110105961A1 (en) 2011-05-05
EP2789684A1 (en) 2014-10-15
US20180044411A1 (en) 2018-02-15
CA2724886A1 (en) 2009-11-26
MX342994B (es) 2016-10-21
KR101537460B1 (ko) 2015-07-16
PL2789684T3 (pl) 2017-06-30
ES2616728T3 (es) 2017-06-14
RU2010152693A (ru) 2012-06-27
KR20150041158A (ko) 2015-04-15
IL248652A0 (en) 2016-12-29
JP2017125073A (ja) 2017-07-20
MX2010012473A (es) 2011-02-23
WO2009143411A2 (en) 2009-11-26
ZA201008209B (en) 2012-04-25
EP3170888A1 (en) 2017-05-24
JP6359051B2 (ja) 2018-07-18
US20120183534A1 (en) 2012-07-19
JP2011521009A (ja) 2011-07-21
AU2009248945B2 (en) 2014-02-13
US20180111982A2 (en) 2018-04-26
EP2294178A4 (en) 2011-12-07
HK1200485A1 (en) 2015-08-07
PT2789684T (pt) 2017-02-14
KR101592156B1 (ko) 2016-02-04
JP6637465B2 (ja) 2020-01-29
JP2022089873A (ja) 2022-06-16
DK2789684T3 (en) 2017-02-20
KR20110000585A (ko) 2011-01-03
IL240242A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
RU2015114990A (ru) Способы, композиции и приборы для облегчения регенерации
BR112014027659A2 (pt) anticorpos específicos para cll-1
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
CR11783A (es) Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno
EP2860192A3 (en) Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
MY153893A (en) Antibodies against human il17 and uses thereof
MY171761A (en) Multispecific antigen-binding molecules and uses thereof
EA200800812A1 (ru) Композиции антитела против cd3
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
EA201100923A1 (ru) Антитела человека против тканевого фактора
UY31710A (es) Anticuerpos monoclonales y su método de obtención
EA201001223A1 (ru) Стабилизированные белковые композиции
EA200870265A1 (ru) Функционально активные антитела
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
UA98332C2 (ru) Гуманизированное антитело к cd44, которое опосредует цитотоксичность в отношении раковых клеток
AR069980A1 (es) Inmunoconjugados dirigidos contra cd 138 y sus usos
RU2014149553A (ru) Биспецифические анти-vegf/анти-ang-2 антитела
MX358705B (es) Agentes de union de esclerostina.
EA201400579A1 (ru) Антитела к il-36r
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
EA200870020A1 (ru) Человеческие моноклональные антитела против о8е
EA201790757A1 (ru) Связывающие антиген cd27l белки